János Szebeni - Publications, H-index & Citations

János Szebeni

semmelweis university

59H指数

240论文数

1.4W被引数

收录论文 70

发表时间

Acute anaphylactic and multiorgan inflammatory effects of Comirnaty in pigs: evidence of spike protein mRNA transfection and paralleling inflammatory cytokine upregulation Comirnaty在猪中引起的急性过敏性及多器官炎症效应：刺突蛋白mRNA转染及伴随的炎症细胞因子上调的证据

British Journal of Pharmacology

IF7.7

2026-07-29

OAAI

László Dézsi; Gábor Kökény; Gábor Szénási; Csaba Révész; Tamás Mészáros; Bálint A. Barta; Réka Facsko; Anna Szilasi; Tamás Bakos; Gergely T. Kozma; Attila B. Dobos; Béla Merkely; Tamás Radovits; János Szebeni

Anti-PEG Immunogenicity of mRNA-LNP Vaccines in Humans: Evidence for Population-Level Changes in the Anti-PEG Antibody Repertoire mRNA-LNP疫苗在人体中的抗PEG免疫原性：关于抗PEG抗体库在人群水平发生变化的证据

Pharmaceutics

IF5.5

2026-07-28

OAAI

Réka Facskó; Tamás Mészáros; Petra Berényi; Zsófia Szabó; János Szebeni; Gergely Tibor Kozma

Unique Features and Collateral Immune Effects of mRNA-LNP COVID-19 Vaccines: Plausible Mechanisms of Adverse Events and Complications mRNA-LNP新冠疫苗的独特特征与伴随免疫效应：不良事件和并发症的可能机制

Pharmaceutics

IF5.5

2026-03-03

OAAI

János Szebeni

Effects of SARS-CoV2 mRNA vaccine on human kidney tubular epithelial cells SARS-CoV2 mRNA疫苗对人类肾小管上皮细胞的影响

Nephrology Dialysis Transplantation

IF5.6

2025-10-01

PREAI

Kokeny, Gabor; Pollok, Julianna; Manzeger, Anna; Szebeni, Janos

Multisystem Endothelial Inflammation: A Key Driver of Adverse Events Following mRNA-Containing COVID-19 Vaccines 多系统内皮炎症：mRNA-Containing COVID-19疫苗相关不良事件的关鍵驱动因素

vaccines

IF0

2025-08-14

OAAI

János Szebeni; Akos Koller

Expanded Spectrum and Increased Incidence of Adverse Events Linked to COVID-19 Genetic Vaccines: New Concepts on Prophylactic Immuno-Gene Therapy, Iatrogenic Orphan Disease, and Platform-Inherent Challenges 与COVID-19基因疫苗相关的扩展谱系和不良反应发生率增加：关于预防性免疫基因疗法、医源性孤儿病及平台固有挑战的新概念

PHARMACEUTICS

IF5.5

2025-03-31

OAAI

Szebeni, Janos

Eculizumab suppresses zymosan-induced release of inflammatory cytokines IL-1a, IL-18, IFN-? and IL-2 in autologous serum-substituted PBMC cultures: Relevance to cytokine storm in Covid-19

BIOMEDICINE & PHARMACOTHERAPY

IF7.5

2023-10-01

OAAI

Bakos, Tamas; Kozma, Gergely T.; Szebeni, Janos; Szenasi, Gabor

Insights into the Structure of Comirnaty Covid-19 Vaccine: A Theory on Soft, Partially Bilayer-Covered Nanoparticles with Hydrogen Bond-Stabilized mRNA-Lipid Complexes 洞察新型冠状病毒肺炎疫苗的结构: 具有氢键稳定的mRNA-脂质复合物的柔软，部分双层覆盖的纳米颗粒的理论

ACS NANO

IF16

2023-07-07

OAAI

Szebeni, Janos; Kiss, Balint; Bozo, Tamas; Turjeman, Keren; Levi-Kalisman, Yael; Barenholz, Yechezkel; Kellermayer, Miklos

Covid-19 vaccines elicit effective IgG responses in an elderly thymus cancer patient with chemotherapy

HUMAN VACCINES & IMMUNOTHERAPEUTICS

IF3.5

2023-04-16

OAAI

Koller, Akos; Szebeni, Janos

Comparative in vitro and in vivo Evaluation of Different Iron Oxide-Based Contrast Agents to Promote Clinical Translation in Compliance with Patient Safety

INTERNATIONAL JOURNAL OF NANOMEDICINE

IF6.5

2023-04-01

OAAI

Unterweger, Harald; Janko, Christina; Folk, Tamara; Cicha, Iwona; Kovacs, Noemi; Gyebnar, Gyula; Horvath, Ildiko; Mathe, Domokos; Zheng, Kang H.; Coolen, Bram F.; Stroes, Erik; Szebeni, Janos; Alexiou, Christoph; Dezsi, Laszlo; Lyer, Stefan

The Hypertensive Effect of Amphotericin B-Containing Liposomes (Abelcet) in Mice: Dissecting the Roles of C3a and C5a Anaphylatoxins, Macrophages and Thromboxane

BIOMEDICINES

IF3.9

2022-07-21

OAAI

Orfi, Erik; Hricisak, Laszlo; Dezsi, Laszlo; Hamar, Peter; Benyo, Zoltan; Szebeni, Janos; Szenasi, Gabor

Applying lessons learned from nanomedicines to understand rare hypersensitivity reactions to mRNA-based SARS-CoV-2 vaccines

NATURE NANOTECHNOLOGY

IF34.9

2022-04-07

OAAI

Szebeni, Janos; Storm, Gert; Ljubimova, Julia Y.; Castells, Mariana; Phillips, Elizabeth J.; Turjeman, Keren; Barenholz, Yechezkel; Crommelin, Daan J. A.; Dobrovolskaia, Marina A.

A naturally hypersensitive porcine model may help understand the mechanism of COVID-19 mRNA vaccine-induced rare (pseudo) allergic reactions: complement activation as a possible contributing factor

GEROSCIENCE

IF5.4

2022-02-11

OAAI

Dezsi, Laszlo; Meszaros, Tamas; Kozma, Gergely; H-Velkei, Maria; Olah, Csaba Zs; Szabo, Miklos; Patko, Zsofia; Fulop, Tamas; Hennies, Mark; Szebeni, Miklos; Barta, Balint Andras; Merkely, Bela; Radovits, Tamas; Szebeni, Janos

A porcine model of hemodialyzer reactions: roles of complement activation and rinsing back of extracorporeal blood

RENAL FAILURE

IF3

2021-12-09

OAAI

Petho, Akos; Piecha, Dorothea; Meszaros, Tamas; Urbanics, Rudolf; Moore, Christoph; Canaud, Bernard; Rosivall, Laszlo; Mollnes, Tom Eirik; Steppan, Sonja; Szenasi, Gabor; Szebeni, Janos; Dezsi, Laszlo

COVIDOUTCOME-estimating COVID severity based on mutation signatures in the SARS-CoV-2 genome

DATABASE-THE JOURNAL OF BIOLOGICAL DATABASES AND CURATION

IF3.6

2021-06-26

OAAI

Nagy, Adam; Ligeti, Balazs; Szebeni, Janos; Pongor, Sandor; Gyrffy, Balazs

Mini-Factor H Modulates Complement-Dependent IL-6 and IL-10 Release in an Immune Cell Culture (PBMC) Model: Potential Benefits Against Cytokine Storm

FRONTIERS IN IMMUNOLOGY

IF5.9

2021-04-28

OAAI

Kozma, Gergely Tibor; Meszaros, Tamas; Bakos, Tamas; Hennies, Mark; Bencze, Daniel; Uzonyi, Barbara; Gyorffy, Balazs; Cedrone, Edward; Dobrovolskaia, Marina A.; Jozsi, Mihaly; Szebeni, Janos

The Critical Choice of Animal Models in Nanomedicine Safety Assessment: A Lesson Learned From Hemoglobin-Based Oxygen Carriers

FRONTIERS IN IMMUNOLOGY

IF5.9

2020-10-26

OAAI

Bedocs, Peter; Szebeni, Janos

Complement Activation: A Potential Threat on the Safety of Poly(ethylene glycol)-Coated Nanomedicines

ACS NANO

IF16

2020-07-09

PREAI

Gabizon, Alberto; Szebeni, Janos